

## **PUBLICATIONS 2000-2010**

1. Reeves HL, Thompson MG, Dack C, Burt AD, Day CP. The role of phosphatidic acid in platelet-derived growth factor - induced proliferation of rat hepatic stellate cells. *Hepatology* 2000;31:95-100.
2. Reeves HL, Dack C, Peak M, Burt AD, Day CP. Stress activated protein kinases in the activation of rat hepatic stellate cells in culture. *J Hepatol* 2000;32:465-472.
3. Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. *Gut* 2000;46:540-5
4. Aithal GP, Day CP, Leathart JBS, Daly AK. Relationship of polymorphism in *CYP2C9* to genetic susceptibility to diclofenac-induced hepatitis. *Pharmacogenetics* 2000;10:1-8.
5. Day CP. Effect of Class III drugs on dispersion of repolarization in patients with myocardial infarction. *In: Dispersion of Ventricular Repolarization: State of the Art.* (Olsson S.B., Yuan S, Amlie J.P., Eds) Futura Publishing Company, Inc. Armonk, New York USA. 2000:289-296.
6. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. *J Hepatol* 2000;33:949-52.
7. Day C.P. Who gets alcoholic liver disease: nature or nurture? *J Royal Coll Phys* 2000;34:557-62.
8. Stewart SF, Manas D, Talbot D, Hudson M, Day CP. Mycophenolate Mofetil monotherapy in liver
9. transplantation. *Lancet* 2001;357:609-10.
10. Day CP. Apoptosis and acute alcoholic hepatitis. *J Hepatol* 2001;34:330-333.
11. Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of a polymorphism in the interleukin-4 gene with Crohn's diseases. *Genes and Immunity* 2001;2:44-47.
12. Mitchell SA, Grove J, Spurland A, Boberg KM, Fleming KA, Day CP, Schrupf E, Chapman RW, and The European Study Group Of Primary Sclerosing Cholangitis. Association of the tumour necrosis factor  $\alpha$  -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. *Gut* 2001;49: 288-294.
13. Day CP, Daly AK. The genetic basis for non-alcoholic and alcoholic steatohepatitis, *In: Steatohepatitis (NASH and ASH).* Falk Symposium 121. (Leuschner U., James O.F.W. & Dancygier H., Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands. 2001:43-53.
14. Day CP, Jones DEJ., Stewart SF. Alcoholic liver disease: new insights into mechanisms and preventative strategies. *Trends in Molecular Medicine* 2001;7:408-13
15. Stewart SF, Day CP. Liver disorder and the HFE locus. *Q J Med* 2001;94:453-56
16. Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, Hudson M. Role of polymorphisms in the interleukin-10 in determining disease susceptibility and phenotype in inflammatory bowel disease. *Digestive Diseases and Sciences.* 2001;46: 1520-5.
17. Burt AD, Day CP. Pathophysiology of the liver. *In: Pathology of the Liver.* (MacSween R, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP, Eds). Harcourt Publishers Limited, Edinburgh. 2001; Chapter 2: 67-105.
18. Day CP. Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis. *GUT* 2001;49:750-1.
19. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. *Brit J Clin Pharmacol* 2001;52:489-99.

20. Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani, V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. *Free Radical Biology & Medicine* 2002;32:38-45.
21. Neuberger J, Schulz K-H, Day CP, Fleig W, Berlakovich GA, Berenguer M, Pageaux G-P, Lucey M, Horsmans Y, Burroughs A, Hockerstedt K. Transplantation for alcoholic liver disease. *J Hepatol* 2002;36:130-7.
22. Reeves HL, Day CP. Extrahepatic effects of alcohol: an overview. *In: Ethanol and the liver.* (Sherman D., Preedy V. & Watson R. , Eds) Taylor & Francis Books, London, UK. 2002;Chapter 18: pp 451-71.
23. Day CP. Non-alcoholic steatohepatitis: where are we now and where are we going? *Gut* 2002;5:585-588
24. Elabbadi N, Day CP, Virden CP, Yeaman SJ. Regulation of phosphatidic acid phosphohydrolase 1 by fatty acids. *Lipids* 2002;37:69-73.
25. Daly AK, Day CP, Donaldson PT. Polymorphisms in immunoregulatory genes: towards individualized immunosuppressive therapy? *Am J Pharmacogenomics* 2002;2(1):13-23.
26. Donaldson PT, Day CP. Predictive value of cytokine polymorphisms for liver disease. Chapter 21 *In: Cytokines in liver injury and repair.* Falk Symposium 125. (Gressner AM, Heinrich PC, & Matern S. Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands. 2002:253-268.
27. Aithal GP, Day CP. Hepatic ADRs. Chapter 37 *In: Pharmacovigilance* (Mann RD, EB Andrews Editors). John Wiley & Sons Ltd. Chichester, UK. 2002:459-74
28. Day CP. Nash-related liver failure: one hit too many? *Am J Gastroenterology* 2002;97:1872-4.
29. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. *Brit J Clin Pharm* 2002;53:408-9.
30. Day CP. Pathogenesis of steatohepatitis. *Balliere's Best Practice and Research in Clinical Gastroenterology* 2002;16:663-78.
31. Day CP. Alcohol and the liver. *Medicine* 2002;30:11:18-20.
32. Day CP, Saksena S. Non-alcoholic steatohepatitis: Definitions and pathogenesis. *J Gastro Hepatol* 2002;17 (Suppl 3):S377-S384.
33. Stewart SF, Leathart JB, Chen Y, Daly AK, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. The valine-alanine manganese superoxide dismutase polymorphism is not associated with increased oxidative stress or susceptibility to advanced alcoholic liver disease. *Hepatology* 2002;36:1355-60.
34. Vidali, M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Jones DEJ, Leathart JB, Day CP, Albano E. Genetic and epigenetic factors in auto-immune reactions towards cytochrome P4502E1 in alcoholic liver disease. *Hepatology* 2003;37:410-9.
35. Stewart SF, Day CP. The management of alcoholic liver disease. *J Hepatol* 2003;38: S2-S13.
36. Day CP. Susceptibility to alcoholic liver disease. *Horizons in Medicine* 2003, No 14: 185-196.
37. McCrae CA, Prince MI, Hudson M, Day CP, James OFW, Jones DEJ. Pain as a complication of opiate antagonists for symptom control in cholestasis. *Gastroenterology* 2003;125:591-6.
38. Day CP. Who gets alcoholic liver disease: nature or nurture? *Acta Gastro-Enterologica Belgica* 2003;66:290-291.

39. Stewart SF, Vidali M, Day CP, Albano E, Jones DEJ. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. *Hepatology* 2004;39:197-203.
40. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 2004;126:586-597.
41. Aithal PG, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic adducts, circulating antibodies and cytokine polymorphisms in patients with diclofenac hepatotoxicity. *Hepatology* 2004;39:1430-40.
42. Day CP. Management of alcoholic hepatitis. Chapter 25 In: *Liver diseases: advances in treatment and prevention*. Falk Symposium 137. (Blum HE, Maier KP, Rodes J, Sauerbruch T Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands. 2004:239-249.
43. Stewart SF, Day CP. Alcoholic liver disease. Chapter 12 In: *Principles of medical biology volume 15: the liver in biology and disease* (Bittar EE, Editor). Elsevier Ltd, Oxford, UK 2004:317-360.
44. Day CP. The potential role of genes in nonalcoholic fatty liver disease. *Clin Liver Disease* 2004;8:673-91.
45. Day CP. NASH is a genetically determined disease. Chapter 6 In: *Fatty Liver Disease: NASH and related disorders* (Farrell GC, George J, Hall PM, McCullough AJ, Editors). Blackwell Publishing Ltd, Oxford, UK. 2004: 66-75.
46. Day CP. Non-alcoholic fatty liver disease. Chapter 26 In: *Evidence – based Gastroenterology & Hepatology, 2<sup>nd</sup> Edition* (John McDonald, Andrew Burroughs, Brian Feagan, Editors). BMJ Books, Blackwell Publishing, Oxford, UK. 2004:393-402.
47. Tal-Kremer S, Day CP, Reeves HL. The Genetic Basis of Hepatocellular Cancer. In: S. Ali, S.L. Friedman, D.A. Mann. *Liver Diseases: Biochemical Mechanisms and New Therapeutic Insights*. Science Publishers Inc, New Hampshire 2006. ISBN 1-57808-399-0
48. Elabbadi N, Day CP, Gamouh A, Zyad A, Yeaman SJ. Relationship between the inhibition of phosphatidic acid phosphohydrolase-1 by oleate and oleoyl-CoA ester and its apparent translocation. *Biochimie* 2005;87:437-443.
49. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD. Day CP. Immune response toward lipid peroxidation products as a predictor of the progression of non-alcoholic fatty liver disease (NAFLD) to advanced fibrosis. *Gut* 2005;54:987-993
50. Day CP. Genetic studies to identify fibrosis genes/SNPs in human populations – liver. In: *Methods in Molecular Medicine* 2005;117:315-32.
51. Forrest, EH, Evans C, Stewart SF, Phillips M, Oo Y, McAvoy N, Fisher N, Singhal N, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray L, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and the derivation and validation of the Glasgow Alcoholic Hepatitis Score. *Gut* 2005;54:1174-9.
52. Day CP. Alcoholic liver diseases. Chapter 23 In: *Gut-Liver interactions: Basic and clinical concepts*. Falk Symposium 146. (Blumberg RS, Gangl A, Manns MP, Tilg H, Zeitz M, Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands. 2005:241-248.
53. Day CP. The natural history of NAFLD: remarkably benign in the absence of cirrhosis. *Gastroenterology* 2005;129:375-378.
54. Cortez-Pinto L, De Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. *J Hepatol* 2006;44:197-208.
55. Day CP. From fat to inflammation. *Gastroenterology* 2006;130:207-210.

56. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. *Clin Med* 2006;6:19-25.
57. Tapirdamaz O, Pravica V, Metselaar HJ, Hansen B, Moons L, van Meurs JBJ, Hutchinson IV, Shaw J, Agarwal K, Adams DH, Day CP, Kwekkeboom J. Polymorphisms in the T-cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation. *Gut* 2006;55:863-868.
58. Day CP. Genes or environment to determine ALD and NAFLD. *Liver International*. 2006;26:1021-28
59. Canadian Journal A chat on fat in the liver. *Can J Gastroenterol* 2006;20:461-2.
60. Benitez-Rajal J, Lorite M-J, Burt AD, Day CP, Thompson MG. Phospholipase D and extracellular signal-regulated kinase in hepatic stellate cells. Effects of platelet-derived growth factor and extracellular nucleotides. *Am J Physiol Gastrointest Liver Physiol* 2006; 291:G977-G986.
61. Day CP. Alcohol and the liver. *Medicine* 2006;35 (1) :22-25.
62. \*Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8 and ABCC2 genotypes. *Gastroenterology* 2007;132:272-281.
63. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day CP, Arcaro G. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in type 2 diabetic patients. *Diabetes Care* 2007;30:1212-1218.
64. \*Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a non-invasive system that accurately identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007;45:846-854.
65. Targher G, Bertolini L, Padovani R, Rodella S Arcaro G, Day CP. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis C. *J Hepatol* 2007;46:1126-1132..
66. Stewart SF, Prince M, Bassendine MF, Hudson M, James OFW, Jones DEJ, Record CO, Day CP. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. *J Hepatol* 2007;47:277-283.
67. Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, Haydon G, O'Grady J, Day CP. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. *Gut* 2007;56:1743-1746
68. De Alwis NMW, Day CP. Non-alcoholic fatty liver disease: The mist gradually clears. *J Hepatol* 2008;48: S104-112.
69. Wilfred de Alwis NM, Day CP. Genes and nonalcoholic fatty liver disease. *Curr Diab Rep* 2008;8:156-63.
70. Barclay GA, Barbour J, Stewart S, Day CP, Gilvarry E. Adverse physical effects of alcohol misuse. *Advances in Psychiatric Treatment* 2008;14:139-51.
71. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, Day CP, Rosenberg WM. Non-invasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis panel and exploring simple markers. *Hepatology*. 2008;47:455-460 (joint senior author).
72. Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day CP, Muggeo M. Nonalcoholic fatty

liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients *Diabetologia* 2008;51:444-50.

73. Newton JL, Jones DEJ, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in Non-Alcoholic Fatty Liver Disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. *Gut* 2008; 57:807-13
74. Stickel F, Österreicher CH, Halangk J, Berg T, Homann N, Hellerbrand C, Patsenker E, Schneider V, Friess H, Seitz HK, Leathart JLB, Day CP. Critical evaluation of matrixmetalloproteinase-3 genetic polymorphism as a risk factor for fibrosis in alcoholic liver disease and chronic hepatitis C. *Alc Clin Exp Res* 2008;32:1-7.
75. Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. *Obesity* 2008;16:1394-9
76. Miele L, Beale G, Nobili V, Patman G, Narla G, Leathart J, Bugianesi E, Day CP, Reeves HL. The kruppel like factor 6 (KLF6) genotype is associated with fibrosis in non-alcoholic fatty liver disease (NAFLD) *Gastroenterology* 2008;135:282-291
77. Beale G, Chattopadhyay D, Gray D, Stewart S, Hudson M, Day CP, Trerotoli P, Giannelli G, Manas D, Reeves HL. AFP, PIVKAI, GP3, SCCA-1 and follistatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. *BMC Cancer* 2008, 8:200 doi:10.1186/1471-2407-8-200.
78. De Alwis NMW, Day CP. Liver disease in obesity. In: *Obesity Science to Practice* (Williams G, Fruhbeck G, Eds). Wiley-Blackwell 2009:273-283.
79. Nobili V, Day CP. Childhood NAFLD: a ticking time-bomb? *Gut* 2009;58:1442.
80. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. *Semin Liver Dis* 2009;29:400-411.
81. Day CP. Non-alcoholic fatty liver disease. *Horizons in Medicine* 2009, No 21: 95-101.
82. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabriel M, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP\*, Grieco A. Increased permeability and tight junction alterations in the intestine of patients with non-alcoholic fatty liver disease (NAFLD). *Hepatology* 2009;49:1877-87 (\*joint senior author).
83. Targher G, Solagna E, Tosi F, Castello R, Spiazzi G, Zoppini G, Muggeo M, Day CP, Moghetti P. Abnormal serum alanine amino transferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. *J Endocrinol Invest* 2009 Jun 18. [Epub ahead of print] PMID: 19542757 [PubMed - as supplied by publisher]
84. \*Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, Graham D, Park BK, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP for the DILIGEN study and SAEC. HLA *B\*5701* genotype is a major determinant of drug-induced liver injury due to flucloxacillin: genome-wide and candidate gene studies. *Nat Genet* 2009;41:816-9.
85. Methodological Approach to Tracing Cell Lineage in Human Epithelial Tissues. Fellous TG, McDonald SA, Burkert J, Humphries A, Islam S, De-Alwis NM, Gutierrez-Gonzalez L, Tadrous PJ, Elia G, Kocher HM, Bhattacharya S, Mears L, El-Bahrawy M, Turnbull DM, Taylor RW, Greaves LC, Chinnery PF, Day CP, Wright NA, Alison MR. *Stem Cells*. 2009;27(6):1410-1420.
86. De Alwis N, Hudson G, Burt AD, Day CP, Chinnery PF. Human liver stem cells originate from the canals of Hering. *Hepatology* 2009 Jul 7;50(3):992-993.
87. Runyon BA; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. [Hepatology](#) 2009 49:2087-2107

88. Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, [Day CP](#), Manas DM, Reeves HL. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. *BMC Cancer* 2009;9:271.
89. Frith J, [Day CP](#), Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. *Gerontology* 2009;55(6):607-13.
90. [Newton JL](#), [Pairman J](#), [Wilton K](#), [Jones DE](#), [Day CP](#). Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. *Clin Auton Res*. 2009;19:319-26.
91. Record C, [Day C](#). Britain's alcohol market: how minimum alcohol process could stop moderate drinkers subsidising those drinking at hazardous and harmful levels. *Clin Med* 2009;9:421-5
92. Frith J, [Day CP](#), Robinson L, Elliott C, Jones DEJ, Newton JL. Potential strategies to improve uptake of exercise interventions in NASH. *J Hep* 2010;52:112-116.
93. Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JBS, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviario G, Marchesini G, [Day CP](#), Fargion S. Genetic variants regulating insulin receptor signaling are associated with the severity of liver damage in patients with nonalcoholic fatty liver disease. *Gut* 2010;59:267-73.
94. Forrest EH, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Hayes PC, [Day CP](#). Comparison of the Glasgow Alcoholic Hepatitis Score and the ABIC score for the assessment of alcoholic hepatitis. *Am J Gastroenterology* 2010;105:701-2.
95. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, [Day CP](#), McTernan PG. Elevated endotoxin levels in non-alcoholic fatty liver disease *J Inflamm* 2010, 7:15doi:10.1186/1476-9255-7-15
96. \*Valenti L, Ahmad Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviario G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, [Day CP](#). Homozygosity for the PNPLA3 / adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology* 2010;51:1209-17
97. [Day CP](#). Genetic and environmental susceptibility to non-alcoholic fatty liver disease. *Digestive Diseases* 2010;28:255-60.
98. [Day CP](#). Non-alcoholic fatty liver disease. Chapter 29 In: Evidence – based Gastroenterology & Hepatology, 3<sup>rd</sup> Edition (John McDonald, Andrew Burroughs Eds). BMJ Books, Wiley-Blackwell Publishing, Oxford, UK. 2010:475-?.
99. De Alwis NMW, [Day CP](#). Current and future therapeutic strategies in NAFLD. *Current Pharmaceutical Design* 2010;16:1958-62.
100. Targher G, Zoppini G, Moghetti P, [Day CP](#). [Disorders of Coagulation and Hemostasis in Abdominal Obesity: Emerging Role of Fatty Liver](#). *Semin Thrombosis Haemostasis* 2010;36:41-8.
101. Targher G, [Day CP](#), Bonora E. Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. *N Engl J Med* 2010;363:1341-50.
102. Kendrick SFW, [Day CP](#). Can pentoxifylline secure its place in liver therapeutics?. *Nat Rev Gastro Hep* 2010;7:593-4
103. Seth D, Daly AK, Haber PS, [Day CP](#). A case in point: Genetic similarities in alcoholic and non-alcoholic liver disease. *Hepatology* 2010;51:1463-5.
104. \*Kendrick SFW, O'Boyle G, Mann J, Zeybel M, Palmer J, Jones DEJ, [Day CP](#). Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. *Hepatology* 2010;51:1988-97..

105. Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Wright M, Day CP, Daly AK. A role for the pregnane X receptor in flucloxacillin-induced liver injury. *Hepatology* 2010;51:1656-64.
106. \*Kendrick SFW, Henderson E, Palmer JE, Jones DEJ, Day CP. Theophylline Improves Steroid Sensitivity in Acute Alcoholic Hepatitis. *Hepatology* 2010;52:126-31
107. Ratziu V, Bellentani S, Cortez-Pinto H, Day CP, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 Special Conference. *J Hepatol* 2010;53:372-84
108. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of Nomenclature and Causality Assessment in Drug- Induced Liver Injury: Summary of a Clinical Research Workshop. *Hepatology* 2010;52:730-42.
109. Parkes J, Roderick P, Harris S, Day CP, Mutimer D, Collier J, Lombard M, Alexander G, Ramage J, Dusheiko G, Wheatley M, Gough C, Burt A, Rosenberg W. Enhanced Liver Fibrosis (ELF) test can predict clinical outcomes in patients with mixed aetiology chronic liver disease. *Gut* 2010;59:1245-51.
110. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010;59:1265-69
111. Donaldson, PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. Human Leucocyte Antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. *J Hepatol* 2010;53:1049-1053.
112. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF. POLG determines the risk of sodium valproate induced liver toxicity. *Hepatology* 2010;52:1791-1796.
113. De Alwis N, Aithal G, Bugianesi E, Leathart J, Hudson G, Pyle A, Mowbray C, Henderson E, Burt AD, Chinnery PF, Day CP. Mitochondrial DNA does not contribute to the heritability of nonalcoholic fatty liver disease. *Mitochondrion* 2011;11:234-235.
114. Iwata R, Baur K, Stieger B, Mertens JC, Daly AK, Frei P, Braun J, Vergopoulos A, Stickel F, Sabrane K, Martin IV, Schmitt J, Goetze O, Day CP, Müllhaupt B, Geier A ; Swiss Hepatitis C Cohort Study Group. A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. *Clin Sci (Lond)*. 2011;120:287-296.
115. Targher G, Zoppini G, Day CP, Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. *Gut*. 2010 Dec 15. [Epub ahead of print].
116. Targher G, Day CP. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. *Hepatology*. 2010 Aug 19. [Epub ahead of print].